LenioBio
Latest round
- Series A
Last raised
- Nov 2021
Total raised
- $18M
Investors
- 3
About LenioBio
Remberto Martis, LenioBio GmbH operates as a biotechnology company that provides disruptive protein expression technology.EU4Health. LenioBio GmbH offers ALiCE, which is a cell-free protein expression platform that enables the production of proteins. It is provided with two expression vectors, pALiCE01 and pALiCE02, which are used according to the targeting of the protein of interest. It offers yields of up to 3 mg/mL of protein in batch mode and utilizes tobacco cell lysates, depleted of vacuoles. ALiCE is available as a research kit in three different sizes.
Who invested in LenioBio
3 investors across 2 rounds
See all investors in LenioBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about LenioBio
Who invested in LenioBio?
LenioBio has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has LenioBio raised?
LenioBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did LenioBio last raise money?
LenioBio's most recent round on record is a Series A, in Nov 2021.
What does LenioBio do?
Remberto Martis, LenioBio GmbH operates as a biotechnology company that provides disruptive protein expression technology.
Where is LenioBio headquartered?
LenioBio is headquartered in Düsseldorf, Germany.
Which VCs invest in companies like LenioBio?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at LenioBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like LenioBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.